CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer. In Vitro CT52923 inhibit the PDGFRs and stem cell factor receptor with an IC 50 value of 100 to 200 nM. CT52923 (0.01-30 μM; 24 h) blocks plateletderived growth factor-induced smooth muscle cell migration or fibroblast proliferation with an IC 50 of 64 and 280 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Migration AssayCell Line: Rat A10 smooth muscle cells Concentration: 0.01-30 μM Incubation Time: 24 h Result: Inhibited PDGF-induced cell migration with an IC 50 of 64 nM. In Vivo CT52923 (oral; 5, 15, 30, and 50 mg/kg; twice daily) can significantly inhibit neointima formation following carotid artery injury by oral administration in the rat . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat carotid artery balloon angioplasty model . Dosage: 5, 15, 30, and 50 mg/kg Administration: Oral gavage; twice daily Result: Inhibited PDGF-mediated response to vascular injury. Form:Solid